正高级研究人员

许艳妮

来源:    

作者:    

时间:2021-07-02    

浏览次数:


许艳妮   国家新药(微生物)筛选实验室   研究员   博士生导师

教育背景及工作经历:

2005年毕业于山东大学药学院药学专业,获理学学士学位;2010年毕业于北京协和医学院,微生物与生化药学专业,获博士学位;20109月进入国家新药(微生物)筛选实验室工作;2014年被聘为副研究员;20163月至20173月国家公派留学美国罗彻斯特大学(Universityof Rochester)心血管研究所;2020年聘为研究员,博士生导师。

主要研究方向:抗动脉粥样硬化药物的发现研究

专业研究领域:主要研究兴趣是针对新的潜在药物靶标发现新的抗代谢综合征(包括抗动脉粥样硬化、抗骨质疏松等)药物,并进行分子作用机制、先导物结构改造等。作为负责人获得了国家自然科学基金青年基金、面上项目、国家科技重大专项子课题、重大新药创制计划、协和青年教师基金、中央级公益性科研院所基本科研业务费等项目的资助。目前在读硕士研究生3名,协助指导博士研究生2名;近年来先后派出2名研究生出国访问交流1年。已发表学术论文47篇,其中第一作者或通讯作者(包括并列)发表文章27篇,其中第一作者或通讯作者(包括并列)发表SCI文章19篇,包括EuropeanHeart Journal (IF: 23.239)ATVBEJMCFASEBJTheranosticsJournalof lipid researchAtherosclerosisJournal of the American Heart AssociationActaPharmaceutica Sinica BBiochemical pharmacologyACS Medicinal Chemistry Letters等,获得国家发明专利12项。

代表性论文:

1) Suowen Xu#, Yanni Xu#, Peng Liu#, Shuya Zhang, Huan Liu, Spencer Slavin, Sandeep Kumar, Marina Koroleva, Jinque Luo, XiaoqianWu, Arshad Rahman, Jaroslav Pelisek, Hanjoong Jo, Shuyi Si, Clint L. Miller, and Zheng Gen Jin*. The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis. European Heart Journal. (2019) 40, 2398–2408. (IF: 23.239)

2) Yanni Xu#, Chang Liu# , Xiaowan Han#, Xiaojian Jia, Yongzhen Li , Chao Liu , Ni Li , Lunming Liu , Peng Liu, Xinhai Jiang , Weizhi Wang, Xiao Wang, Yining Li, Mingzhu Chen, Jinque Luo, Xuan Zuo, Jiangxue Han, Li Wang , Yu Du , Yang Xu, Jian-Dong Jiang*, Bin Hong *, Shuyi Si*. E17241 as a Novel ABCA1 (ATP-Binding Cassette Transporter A1) Upregulator Ameliorates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol. 2021 Jan 14; doi: 10.1161/ATVBAHA.120.314156. PMID: 33441025.

3) Jinque Luo#, Xiao Wang#, Xinhai Jiang, Chao Liu, Yongzhen Li, Xiaowan Han, Xuan Zuo, Yining Li, Ni Li, Yanni Xu*, Shuyi Si*, Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport. FASEB J. 2020 Jan;34(1):1398-1411. doi: 10.1096/fj.201900903RRR. Epub 2019 Dec 1.

4) Xinhai Jiang, Yining Li, Weizhi Wang, Xiaowan Han, Jiangxue Han, Mingzhu Chen, Jing Zhang, Chenyin Wang, Shunwang Li, Jinque Luo, Xiao Wang, Yang Xu, Yanni Xu*, Jingcai Cheng*, Shuyi Si*, Nrf2 activator JC-5411 inhibits atherosclerosis through suppression of inflammation and regulation of lipid metabolism, Front Pharmacol. 16 November 2020, https://doi.org/10.3389/fphar.2020.532568

5) Dongsheng Li#, Chao Liu#, Xinhai Jiang, Yuan Lin, Jing Zhang, Yan Li, Xuefu You, Wei Jiang, Minghua Chen*, Yanni Xu*, Shuyi Si*, Design, Synthesis, and Evaluation of Substituted 2-acylamide-1,3-benzo[d]zole Analogues as Agents against MDR- and XDR-MTB, European Journal of Medicinal Chemistry, 2021 Jan 1;209:112898. doi: 10.1016/j.ejmech.2020.112898. Epub 2020 Oct 10.

6) Ni Li#, Xiao Wang, Peng Liu, Duo Lu, Wei Jiang, Yanni Xu*, Shuyi Si*, E17110 promotesreversecholesteroltransport with liver X receptor β agonist activity in vitro. Acta Pharmaceutica Sinica B, 2016;6(3):198–204.

7) Yanni Xu#, Suowen Xu#, Peng Liu#, Marina Koroleva, Shuya Zhang, Shuyi Si, ZhengGen Jin*. Suberanilohydroxamic Acid as a Pharmacological Kruppel-Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis, J Am Heart Assoc, 2017.11.30, 6(12)

8) Yanni Xu#, Qi Liu#, Yang Xu, Chang Liu, Xiao Wang, Xiaobo He, Ningyu Zhu, Jikai Liu, Yexiang Wu, Yongzhen Li, Ni Li, Tingting Feng, Fangfang Lai, Murui Zhang, Bin Hong,* Jian-Dong Jiang,* Shuyi Si.* Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through up-regulating ABCA1 and SR-BI within RCT. Journal of lipid research. 2014 Aug;55(8):1634-47.  

9) Tingting Feng#, Peng Liu#, Xiao Wang, Jinque Luo, Xuan Zuo, Xinhai Jiang, Chang Liu, Yongzhen Li, Ni Li, Minghua Chen, Ningyu Zhu, Xiaowan Han, Chao Liu, Yanni Xu*, Shuyi Si*. SIRT1 activator E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression. Atherosclerosis. 2018 Jul; 274:172-181.

10) Xu S#, Xu Y, Yin M, Zhang S, Liu P, Koroleva M, Si S, Little PJ, Pelisek J, Jin ZG*. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics. 2018 Apr 30;8(11):3007-3021. doi: 10.7150/thno.21966. eCollection 2018.

11) Niu N#, Xu S#*, Xu Y, Little PJ, Jin ZG*. Targeting Mechanosensitive Transcription Factors in Atherosclerosis. Trends Pharmacol Sci. 2019 Feb 27. pii: S0165-6147(19)30035-5. doi: 10.1016/j.tips.2019.02.004.

12) Yanni Xu#, Peng Liu#, Suowen Xu, Marina Koroleva, Shuya Zhang, Shuyi Si*, Zheng Gen Jin*. Tannic acid as a plant-derived polyphenol exerts vasoprotection via enhancing KLF2 expression in endothelial cells. Scientific Reports. 2017 Jul 27;7(1):6686.

13) Chang Liu#, Tingting Feng, Ningyu Zhu, Peng Liu, Xiaowan Han, Minghua Chen, Xiao Wang, Ni Li, Yongzhen Li, Yanni Xu*, Shuyi Si*. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis, Scientific Reports. 2015.4.1, 5: 9530.

14) Ni Li, Xiao Wang, Yongzhen Li, Tingting Feng, Chang Liu, Yanni Xu*, Shuyi Si*. Identification of a novel selective agonist for Liver X Receptor α (LXRα) via Screening. Biochemical pharmacology. 92 (2014) 438–447.

15) Yongzhen Li, Tingting Feng, Chang Liu, Ni Li, Dongsheng Li, Minghua Chen, Xiao Wang, Yanni Xu*, Shuyi Si*. Optimization of Rutaecarpine as ABCA1 up-regulators for treating Atherosclerosis. ACS Medicinal Chemistry Letters. 2014 Jun 24;5(8):884-8.

16) Yanni Xu#, Juan Wang#, Yi Bao, Wei Jiang, Lian Zuo, Danqing Song, Bin Hong, Shuyi Si. Discovery of two novel antagonists of the Scavenger Receptor CD36 through a high throughput screening model. Analytical Biochemistry. 400 (2010) 207–212.

专利:

1)司书毅,许艳妮,刘祺,蒋建东,洪斌,李卓荣,姜威,贺晓波,徐扬,李永臻,来芳芳,巫晔翔, 李霓,王智敏,吴茱萸次碱类化合物的用途,专利申请日,2011.3.21,中国,ZL201110067053.1,授权公告日:2014.8.6

2)司书毅,许艳妮,李永臻,姜威,刘畅,王潇,冯婷婷,李霓,李东升,巫晔翔,一组胺甲酰基苯磺酰类化合物的用途。专利申请日,201364日,ZL201310216995.0,授权公告日,2017412日。

3)司书毅,许艳妮,李永臻,姜威,贺晓波,刘畅,刘祺,王潇,冯婷婷,巫晔翔,N-(4,5-二氢-2-噻唑)-2-(4-甲基苯氧甲基)噻唑-4-甲酰胺的用途,专利申请日:2013.8.1,专利号: ZL201310329640.2,授权日:2018814日。

4)司书毅,许艳妮,洪斌,刘畅,李永臻,刘祺,贾晓健,刘鹏,王潇,一组2-取代甲酰胺基-3-烷氧基吡啶类衍生物及其制药用途,申请日:2015.07.29,专利号:ZL201510455554.5,授权日:2019125日。

5)司书毅,冯婷婷,许艳妮,李永臻,刘鹏,刘畅,陈明华,王潇,李霓,巫晔翔,取代的哌嗪-1,4-二酰胺类化合物在制药中的应用,专利申请日,2014526日。授权号:ZL201410224804.X,授权公告日,2017125日。

6)司书毅,冯婷婷,许艳妮,李永臻,刘鹏,刘畅,陈明华,王潇,李霓,巫晔翔,取代的哌嗪-1,4-二酰胺类化合物在制药汇总的应用,PIPERAZINE-1,4-DI-SUBSTITUTED AMIDES OF THE COMPOUNDS USED IN THE PHARMACEUTICA,香港特别行政区政府知识产权局署专利注册处,专利编号:HK1199826,申请日:2014.5.26,申请编号:15100307.1,授权日:2018323日。

7)司书毅,李永臻,许艳妮,冯婷婷,刘畅,王潇,刘鹏,巫晔翔,贺晓波,李东升,陈明华,刘伟,芳基取代的酰胺类化合物及其制备方法、包含其的药物组合物及其应用,2014.6.17,中国申请号,201410270006.0,专利号:ZL2014102700006.0,授权告日:2018629日。

8)司书毅,洪斌,许艳妮,贾晓健,李永臻,刘畅,王丽,刘祺,一组2-酰胺基-3-烷氧基取代的吡啶化合物及其新用途,申请日:2013.6.21,专利号:ZL201310247772.0,授权日:2018925日。

9)司书毅,冯婷婷,许艳妮,取代的哌嗪-1,4-二酰胺类化合物在制备治疗和/或预防炎症反应的药中的应用。申请号:ZL 201610251864.X,申请日:2014526日。授权日,20190118日。

10)司书毅,冯婷婷,许艳妮,取代的哌嗪-1,4-二酰胺类化合物在制备治疗和/或预防衰老反应的药中的应用。专利号:ZL201610251822.6,申请日:2014526日。授权日,20181116日。

11)司书毅,韩小婉,许艳妮,姜威,宫世强,贺晓波,刘超,王潇,罗金雀,左璇,姜新海,一组具有抗骨质疏松活性的化合物及其应用,申请号:ZL201910090949.8,申请日:2019.1.30;授权日,20201218日。

12)司书毅,李霓,李永臻,许艳妮,刘畅,冯婷婷,贺晓波,刘伟,巫晔翔,王潇,一组2,3-二取代的苯并喹唑啉类的肝X受体的激动剂及用途,专利申请日:2013.5.15,专利号:ZL201310178164.9,授权日:2018713日。

13)司书毅,李霓,李东升,许艳妮,李永臻,刘畅,冯婷婷,姜威,刘伟,贺晓波,巫晔翔,王潇,一组取代的苯甲酰胺类的肝X受体的激动剂及用途,专利申请日:2013.5.15,专利号:ZL201310178186.5,授权日:2018713日。

14)司书毅,许艳妮,王潇、罗金雀、李永臻、刘超、姜新海、李依宁、韩小婉、李妍、陈明华、张晶、甄心,一组四氢吲哚并喹唑啉类化合物及其应用,申请号:201910948669.6,申请日:2019.10.8

荣誉奖励:获得SLASTony B. Academic Travel AwardSLAS青年科学家旅行奖)、中国医学科学院北京协和医学院第三届青年科技人员创新论坛三等奖、第十二届抗生素学术会议优秀论文奖、《药学学报》第七届优秀研究论文奖等。

学术任职:

1)中国病理生理学会动脉粥样硬化专业委员会、国际动脉粥样硬化分会中国分会胆固醇逆向转运专家组委员;

2)第九届中国药学会抗生素专业委员会秘书;

3)美国心脏协会(AHA)成员;

4)中国药学会高级会员;

5Frontier in Pharmacology等杂志审稿人等。

联系电话:010-6318062313466708639

电子邮箱:xuyanni2010@imb.pumc.edu.cn